Anti-TEM1 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-11078285-B2
Application number	US-201816231876-A
Country	US
Kind code	B2
Filing date	Dec 24, 2018
Priority date	Nov 11, 2009
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

First claim

What is claimed is:

1. A method of diagnosing the presence of a tumor or a cancer growth in a subject, said method comprising: (a) isolating a tissue sample from said subject; and (b) sampling said tissue sample isolated from said subject with a composition comprising an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment is specific for both the mouse and human form of an endosialin tumor endothelial marker 1 (TEM1) and binds to an epitope sequence as set forth in SEQ ID NO: 40, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising a CDR1 sequence of residues 31 to 35 of SEQ ID NO: 43; a CDR2 sequence of residues 50 to 65 of SEQ ID NO: 43; and a CDR3 sequence of residues 98 to 102 of SEQ ID NO: 43, and wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising a CDR1 sequence of residues 23 to 36 of SEQ ID NO: 48; a CDR2 sequence of residues 52 to 62 of SEQ ID NO: 48; and a CDR3 sequence of residues 97 to 104 of SEQ ID NO: 48, whereby specific binding of said antibody or antigen-binding fragment to said tissue sample is indicative of the presence of a tumor or cancer growth in said subject.

2. The method of claim 1 , further comprising a secondary reagent that specifically binds to said antibody or antigen-binding fragment but does not antagonize binding of said antibody or antigen-binding fragment to its target.

3. The method of claim 2 , whereby said secondary reagent is a photoactivatable agent, a fluorophore, a radioisotope, a bioluminescent protein, a bioluminescent peptide, a fluorescent tag, a fluorescent protein, or a fluorescent peptide.

4. The method of claim 1 , whereby said sampling comprises the step of analyzing said sample using a chromogenic immunological assay.

5. The method of claim 4 , whereby said sampling comprises the step of analyzing said sample using microscopic imaging.

Assignees

• Univ Pennsylvania

Inventors

• Scholler Nathalie
• Zhao Aizhi
• Siegel Donald
• Coukos George

Classifications

• C07K16/2851 Primary

  against the lectin superfamily, e.g. CD23, CD72 · CPC title

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61K2039/505

  comprising antibodies · CPC title